Head-To-Head Comparison: Organon & Co. (OGN) versus Its Rivals

Organon & Co. (NYSE:OGN) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Organon & Co. to similar businesses based on the strength of its analyst recommendations, institutional ownership, earnings, profitability, valuation, risk and dividends.

Profitability

This table compares Organon & Co. and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.49%	82.06%	6.03%
Organon & Co. Competitors	-2,381.20%	-218.66%	-15.76%

Volatility and Risk

Organon & Co. has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Organon & Co.’s competitors have a beta of -3.76, meaning that their average share price is 476% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Organon & Co. and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2	5	0	0	1.71
Organon & Co. Competitors	7777	13864	25736	1034	2.41

Organon & Co. presently has a consensus target price of $11.40, indicating a potential downside of 17.72%. As a group, “Pharmaceuticals” companies have a potential upside of 23.74%. Given Organon & Co.’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Organon & Co. has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares Organon & Co. and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Organon & Co.	$6.22 billion	$187.00 million	18.23
Organon & Co. Competitors	$3.56 billion	$3.19 billion	548.12

Organon & Co. has higher revenue, but lower earnings than its competitors. Organon & Co. is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Dividends

Organon & Co. pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Organon & Co. pays out 10.5% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.2% and pay out 48.2% of their earnings in the form of a dividend.

Institutional and Insider Ownership

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.6% of Organon & Co. shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Organon & Co. competitors beat Organon & Co. on 8 of the 15 factors compared.

Organon & Co. Company Profile

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.